Wound healing

Abstract

A composition for use in the treatment of wounds to inhibit scar tissue formation during healing is disclosed, comprising an effective activity-inhibiting amount of a growth factor neutralizing agent or agents specific against only fibrotic growth factors together with a pharmaceutically acceptable carrier. The method of preparation of the composition and method of administering the composition to a host suffering from tissue wounding is also disclosed.

1 - 27 . (canceled)  
   
   
       28 . A method of inhibiting scar tissue formation during the healing of a wound, comprising the step of administering to a host suffering from tissue wounding an agent that specifically neutralizes the fibrotic activity of a fibrotic growth factor selected from the group consisting of TGF beta 1, TGF beta 2, and PDGF, wherein said agent neutralizes the stimulation of macrophage infiltration, fibroblast migration, extracellular matrix synthesis or deposition by fibroblasts, in the wound area, wherein said agent is administered in an amount sufficient to effect said inhibition of scar tissue formation.  
   
   
       29 . The method of  claim 28 , wherein said agent is an antisense oligonucleotide to mRNA encoding said growth factor.  
   
   
       30 . The method of  claim 28 , wherein said agent is a ribozyme to mRNA encoding said growth factor.  
   
   
       31 . The method of  claim 28 , wherein said agent is a soluble peptide containing a receptor binding domain of said growth factor.  
   
   
       32 . The method of  claim 28 , wherein said agent is a molecule that binds specifically to said growth factor to inhibit receptor binding.  
   
   
       33 . The method of  claim 28 , wherein said agent is a soluble peptide comprising a growth factor binding domain of a receptor for said growth factor.  
   
   
       34 . The method of  claim 28 , wherein said agent is administered prior to the granulation phase of wound healing.  
   
   
       35 . The method of  claim 28 , wherein said agent is administered during the granulation phase of wound healing.  
   
   
       36 . The method of  claim 28  wherein said agent is an antisense oligonucleotide to mRNA encoding said growth factor and said agent is administered prior to or during the granulation phase of wound healing.